Heterogeneity of paracetamol metabolism in Gilbert’s syndrome

  • A. Esteban
  • M. Pérez-Mateo


Gilbert’s syndrome (GS) is an inherited bilirubin UDP-glucuronosyl transferase deficiency. The object of this study was to investigate the possible effects of this disorder on the metabolism of a drug, such as paracetamol, which is basically eliminated by hepatic glucuronidation. We studied 32 healthy volunteers and 18 people with GS, all of whom were given 1.5 g of paracetamol orally. In the 24 h urine collected, we determined the elimination of free paracetamol, the conjugates (glucuronide, sulphate) and the oxidation products (cysteine, mercapturic acid) by high pressure liquid chromatography (HPLC). The results are given as a percentage of the total quantity of paracetamol eliminated. The patients with GS were divided into 2 subgroups (GS-I and GS-II) according to whether glucuronidation was more or less than 50%. The overall results of the GS group showed no significant difference in the urinary elimination of metabolites as compared to the control group. However, in subgroup GS-I, a reduction in glucuronidation (P=0.0012) and an increase in oxidation (P=0.0051) was seen, as compared with the other 2 groups. There was inverse correlation between the glucuronide produced by conjugation and the oxidation products (r=−0.8718;P<0.005). People with GS are a heterogeneous group with respect to the metabolism of paracetamol. In one subgroup this was normal. In the other subgroup there was a marked reduction in glucuronidation and an increase in oxidation. These changes could mean that people in this subgroup are more liable to liver damage after an overdose of paracetamol.


Paracetamol metabolism Gilbert’s syndrome paracetamol conjugates hepatotoxicity glucuronidation 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Thomson J.S., Prescott L.F. (1966): Liver damage and impaired glucose tolerance after paracetamol overdose. BMJ 2: 506–507.CrossRefPubMedGoogle Scholar
  2. 2.
    Mitchell J.R., Thorgeirsson S.S., Potter W.Z., Jollow D.J., Keiser H. (1974): Acetaminophen-induced hepatic injury: protective role of glutathione in man and rationale for therapy. Clin. Pharmacol. Ther., 16: 676–684.PubMedGoogle Scholar
  3. 3.
    Prescott L.F. (1983): Paracetamol overdosage. Pharmacological considerations and clinical management. Drugs, 25: 290–314.CrossRefPubMedGoogle Scholar
  4. 4.
    Aono S., Adachi V., Uyama E. et al. (1995): Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert’s syndrome. Lancet, 345: 958–959.CrossRefPubMedGoogle Scholar
  5. 5.
    Ebner T., Burchell B. (1993): Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family. Drug Metab. Dispos., 21: 50–55.PubMedGoogle Scholar
  6. 6.
    Owens I.S., Ritter J.K. (1992): The novel bilirubin/phenol UDP-glucuronosyltransferase UGT1 gene locus: implications for multiple nonhemolytic familial hyperbilirubinemia phenotypes. Pharmacogenetics, 2: 93–108.CrossRefPubMedGoogle Scholar
  7. 7.
    de Morais S.M.F., Wells P.G. (1989): Enhanced acetaminophen toxicity in rats with bilirubin glucuronyl transferase deficiency. Hepatology, 10: 163–167.CrossRefPubMedGoogle Scholar
  8. 8.
    Schmid R., Hammaker L. (1959): Glucuronide formation in patients with constitutional hepatic dysfunction (Gilbert’s disease). N. Engl. J. Med., 260: 1310–1314.CrossRefPubMedGoogle Scholar
  9. 9.
    Douglas A.P., Savage R.L., Rawlins M.D. (1978): Paracetamol (Acetaminophen) kinetics in patients with Gilbert’s syndrome. Eur. J. Clin. Pharmacol., 13: 209–212.CrossRefPubMedGoogle Scholar
  10. 10.
    Ullrich D., Sieg A., Blume R., Bock K.W., Schröter W., Bircher J. (1987): Normal pathways for glucuronidation, sulphation and oxidation of paracetamol in Gilbert’s syndrome. Eur. J. Clin. Invest., 17: 237–240.CrossRefPubMedGoogle Scholar
  11. 11.
    de Morais S.M.F., Uetrecht J.P., Wells P.G. (1992): Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert’s syndrome. Gastroenterology, 102: 577–586.PubMedGoogle Scholar
  12. 12.
    Esteban A., Pérez-Mateo M. (1993): Gilbert’s disease: a risk factor for paracetamol overdosage? J. Hepatol., 18: 257–258.CrossRefPubMedGoogle Scholar
  13. 13.
    Esteban A., Graells M., Satorre J., Pérez-Mateo M. (1992): Determination of paracetamol and its four major metabolites in mouse plasma by reversed-phase ion-pair high-performance liquid chromatography. J. Chromatogr., 573: 121–126.CrossRefPubMedGoogle Scholar
  14. 14.
    Critchley J.A.J.H., Nimmo G.R., Gregson C.A., Woolhouse N.M., Prescott L.F. (1986): Inter-subject and ethnic differences in paracetamol metabolism. Br. J. Clin. Pharmacol., 22: 649–657.PubMedGoogle Scholar
  15. 15.
    Lee H.S., Ti T.Y., Koh Y.K., Prescott L.F. (1992): Paracetamol elimination in Chinese and Indians in Singapore. Eur. J. Clin. Pharmacol., 43: 81–84.CrossRefPubMedGoogle Scholar
  16. 16.
    Patel M., Tang B.K., Kalow W. (1992): Variability of acetaminophen metabolism in Caucasians and Orientals. Pharmacogenetics, 2: 38–45.CrossRefPubMedGoogle Scholar
  17. 17.
    Esteban A., Pérez-Mateo M. (1993): El metabolismo del paracetamol en voluntarios sanos: estudio de una muestra en población española. Gastroenterol. Hepatol., 16: 55–60.Google Scholar
  18. 18.
    Esteban A., Calvo R., Pérez-Mateo M. (1996): Paracetamol metabolism in two ethnically different Spanish populations. Eur. J. Drug Metab. Pharmacokinet., 21: 233–239.CrossRefPubMedGoogle Scholar
  19. 19.
    Clements J.A., Critchley J.A.J.H., Prescott L.F. (1984): The role of sulphate conjugation in the metabolism and disposition of oral and intravenous paracetamol in man. Br. J. Clin. Pharmacol., 18: 481–485.PubMedGoogle Scholar
  20. 20.
    Mucklow J.C., Fraser H.S., Bulpitt J., Kahn C., Mould G., Dollery C.T. (1980): Environmental factors affecting paracetamol metabolism in London factory and office workers. Br. J. Clin. Pharmacol., 10: 67–74.PubMedGoogle Scholar
  21. 21.
    Prescott L.F. (1987): Environmental modulation of paracetamol toxicity. In: Plaa G.L., Du Souich P., Erill S. (Eds) Interactions between drugs and chemicals in industrial societies. Esteve Foundation Symposia, vol 2. Amsterdam: Elsevier, 161–174.Google Scholar
  22. 22.
    Nash R.M., Stein L., Penno M.B., Passananti G.T., Vesell E.S. (1984): Sources of interindividual variations in acetaminophen and antipyrine metabolism. Clin. Pharmacol. Ther., 36: 417–430.PubMedGoogle Scholar
  23. 23.
    Bosma P.J., Chowdhury J.R., Huang al. (1992): Mechanisms of inherited deficiencies of multiple UDP-glucuronosyltransferase isoforms in two patients with Crigler-Najjar syndrome, type I. FASEB J., 6: 2859–2863.PubMedGoogle Scholar
  24. 24.
    Ritter J.K., Yeatman M.T., Ferreira P., Owens I.S. (1992): Identification of a genetic alteration in the code for bilirubin UDP-glucuronosyltransferase in the UGT1 gene complex of a Crigler-Najjar type I patient. J. Clin. Invest., 90: 150–155.CrossRefPubMedGoogle Scholar
  25. 25.
    Bosma P.J., Chowdhury J.R., Bakker al. (1995): The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome. N. Engl. J. Med., 333: 1171–1175.CrossRefPubMedGoogle Scholar
  26. 26.
    Mathew P. (1996): The genetic basis of Gilbert’s disease [comment]. N. Engl. J. Med., 334: 802–803.PubMedGoogle Scholar
  27. 27.
    Monaghan G., Ryan M., Seddon R., Hume R., Burchell B. (1996): Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert’s syndrome. Lancet, 347: 578–581.CrossRefPubMedGoogle Scholar
  28. 28.
    Sato H., Adachi Y., Koiwai O. (1996): The genetic basis of Gilbert’s syndrome [comment]. Lancet, 347: 557–558.CrossRefPubMedGoogle Scholar
  29. 29.
    Bock K.W., Forster A., Gschaidmeier al. (1993): Paracetamol glucuronidation by recombinant rat and human phenol UDP-glucuronosyltransferases. Biochem. Pharmacol., 45: 1809–1814.CrossRefPubMedGoogle Scholar
  30. 30.
    Bock K.W., Schrenk D., Forster al. (1994): The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics, 4: 209–218.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 1999

Authors and Affiliations

  • A. Esteban
    • 1
  • M. Pérez-Mateo
    • 2
  1. 1.Research Unit, Universidad Miguel HernandezHospital General Universitario de ElcheAlicante
  2. 2.Department of Internal Medicine, Universidad Miguel HernandezHospital General Universitario de AlicanteAlicanteSpain

Personalised recommendations